Author: Yépez, Joana Estephany Gordillo ; Marangon, Renata Machado ; Tanaka, Orlando Motohiro ; Salvação, Sara Moreira Leal ; Ignácio, Sergio Aparecido ; de Viveiros, Bruno Massa ; Andreis, Patricia Kern Di Scala ; Camargo, Elisa Souza ; Guariza-Filho, Odilon ; Johann, Aline Cristina Batista Rodrigues ; Vosgerau, Luana

OBJECTIVEWe evaluated whether the use of botulinum neurotoxin type A (BTX-A) in masticatory muscles influences tooth movement and bone remodeling.DESIGNSeventy-seven male Wistar rats were allocated to the groups: S - Saline (n=20); SM - Saline with movement (n=20); BT - Botulinum toxin (n=18); BTM - Botulinum toxin with movement (n=19). On day 1, 0.02 mL of sterile 0.9 % saline was administered to groups S and SM and BTX-A (1 U in 0.02 mL of saline) to groups BT and BTM, in the masseter and temporal muscles laterally. On day 30, a nickel titanium spring was installed to move the first maxillary molar and euthanasia was performed on days 32 and 51. Tooth displacement, maxillary and mandibular bone volumes, collagen neoformation, bone and root resorptions, and masseter morphometry were assessed. Statistical analysis was conducted (p < 0.05).RESULTSA higher percentage of type I collagen was observed in the BT than in the S group on day 51 and lower mass, length, and diameter of the masseter fibers in BT and BTM (p < 0.05). Tooth displacement, bone volume, bone and root resorptions, hyaline area, and masseter height showed no difference among groups with and without BTX-A, regardless of tooth movement (p > 0.05).CONCLUSIONSBTX-A did not interfere with tooth displacement, bone volume, and dental and periodontal tissues related to tooth movement in rats; it increased mature collagen in animals without tooth movement; and it caused a decrease in the mass, length, and diameter of the masseter fibers.

01 Oct 2024·International Wound Journal

Biodegradable Temporising matrix in the reconstruction of complex wounds: A systematic review and meta‐analysis

Review

Author: Aziz, Fouad Tariq ; Nordin, Mohamad Nazmi M. ; Kastritsi, Olga ; Rahman, Shafiq ; Matzakanis, Georgios ; Asaju, Ayobami ; Braimah, Fatima ; Fitzpatrick, Niall James ; Lane, George ; Rollett, Rebecca

AbstractObjectiveTo assess the efficacy of biodegradable temporising matrix (BTM) in complex wound reconstruction.MethodsThe authors conducted a systematic review and meta‐analysis as per the preferred reporting items for systematic review and meta‐analysis (PRISMA) guidelines following a literature search assessing BTM in complex wound reconstruction. The primary outcome measures included the proportion of BTM integration as well as integration time. Secondary outcomes included graft take over BTM, infection rate and other complications as well as scar outcome.ResultsTwenty six studies met the inclusion criteria with a total of 1153 complex wounds. The mean proportional integration was 92.7% at (95% confidence intervals [CI] 88.57, 96.87, p < 0.001) with a mean integration time of 34.05 days (95% CI 33.33, 34.79, p < 0.001). The infection rate was low at 12.6% with an untransformed proportion metric assessment (0.126, 0.08–0.168, p < 0.001) at the site of BTM application. Favourable scar outcomes were reported using the matching assessment using photographs with scars (MAPS) and patient and observer scar assessment scales (POSAS).ConclusionBTM offers a robust dermal template in reconstruction of complex wounds. The authors recommend for randomised controlled trials to enhance the current evidence base.

01 Sep 2024·Journal of Hand Surgery Global Online

Novosorb Biodegradable Temporizing Matrix for Reconstruction of Complex Upper-Extremity Wounds

Article

Author: Jou, Christopher ; Chepla, Kyle J. ; Chepla, Kyle J

PurposeDermal matrices can be used in management of upper-extremity wounds to create vascularized wound beds in the setting of exposed bone or tendon. Early outcomes of Novosorb biodegradable temporizing matrix (BTM) demonstrated success when used in the treatment of complex wounds. We hypothesize that BTM is effective for reconstruction of upper-extremity wounds.MethodsA retrospective review was performed for patients who underwent reconstruction of upper-extremity wounds with BTM between January 2017 and May 2022.ResultsIn total, 51 patients (39 males and 12 females) were included. Wound etiology included trauma (n = 30), burn (n = 12), infection (n = 8), and vasopressor-related injury (n = 1). The average size of BTM was 162.5 cm², and the average time from BTM application to wound closure was 90.1 days. Twenty-seven (52.9%) patients required skin grafting, whereas 20 (39.2%) did not and re-epithelialized spontaneously. Those who did not require skin grafting had significantly smaller wound sizes compared to those who required skin grafting (58.5 cm² vs 248.6 cm²; P = .002). Complications occurred in 14 patients, including infection (n = 5), fluid collection (n = 5), and template dehiscence (n = 4). Wound closure was successful in 92% of patients.ConclusionsNovosorb BTM is effective for the management of upper-extremity wounds with exposed bone and tendon.Clinical relevanceIn the management of complex upper-extremity wounds with exposed bone and tendon, even when devoid of paratenon or periosteum, Novosorb BTM provides a safe and effective alternative to more complex reconstructive options.

100 Deals associated with PB(CT)-4010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Preclinical	FI	Paras Biopharmaceuticals Finland Oy	07 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

PB(CT)-4010

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation